8月25日，锦欣生殖披露2025财年中报。 8月25日，锦欣生殖(01951)盘中上涨5.28%，截至10:17，报3.39元/股，成交9395.98万元。 锦欣生殖医疗集团有限公司是中美领先的辅助生殖服务机构，拥有和经营多家医院和医疗中心，主要提 供辅助生殖服务及相关治疗。根据弗若斯特沙利文报告，2018年，公司在中国辅助生殖服务市场中排名 第三，进行了20,958个体外受精取卵周期，市场份额约为3.1%，在非国有辅助生殖服务机构中排名第 一。 截至2024年年报，锦欣生殖营业总收入28.12亿元、净利润2.83亿元。 本文源自：金融界 作者：行情君 ...

Group 1 - The core viewpoint of the article highlights the performance of the Sci-Tech Chip ETF (588290), which opened with a gain of 1.43% at 2.051 yuan [1] - The top holdings of the Sci-Tech Chip ETF include companies such as SMIC, which rose by 1.95%, and Haiguang Information, which increased by 5.34% [1] - The fund's performance benchmark is the Shanghai Stock Exchange Sci-Tech Board Chip Index, managed by Huaan Fund Management Co., with a return of 98.32% since its inception on September 30, 2022, and a return of 32.13% over the past month [1]

Group 1 - The top three companies with the highest short positions as of August 15 are WuXi AppTec (02359), CATL (03750), and COSCO Shipping Holdings (01919), with short ratios of 14.92%, 14.41%, and 13.40% respectively [1][2] - The companies with the largest absolute increase in short positions are Heng Rui Medicine (01276), Yao Cai Securities (01428), and Modern Animal Husbandry (01117), with increases of 2.49%, 1.34%, and 1.31% respectively [1][2] - The companies with the largest absolute decrease in short positions are Ganfeng Lithium (01772), WuXi AppTec (02359), and Fourth Paradigm (06682), with decreases of -2.98%, -2.67%, and -2.28% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include Ping An Insurance (02318) at 12.46%, Green Leaf Pharmaceutical (02186) at 12.36%, and Vanke Enterprises (02202) at 12.13% [2] - The companies with the most significant increases in short ratios include Heng Rui Medicine (01276) from 0.51% to 2.99%, Yao Cai Securities (01428) from 3.47% to 4.81%, and Modern Animal Husbandry (01117) from 4.74% to 6.05% [2] - The companies with the most significant decreases in short ratios include Ganfeng Lithium (01772) from 13.32% to 10.34%, WuXi AppTec (02359) from 17.59% to 14.92%, and Fourth Paradigm (06682) from 2.74% to 0.46% [2][3]

Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies. Group 1: Companies with Increased Holdings - Beijing Mechanical and Electrical Holdings (00187) saw an increase of 3.04%, bringing its latest holding percentage to 45.45% [2] - Yimai Sunshine (02522) also increased by 3.04%, with a current holding of 39.10% [2] - Anjoy Foods (02648) experienced a rise of 1.93%, now holding 10.60% [2] - Other notable increases include Yashang Service (03319) at +1.81% (29.17%), and Shenwan Hongyuan (06806) at +1.47% (42.19%) [2] Group 2: Companies with Decreased Holdings - The Yingfu Fund (02800) faced the largest decrease at -3.86%, with a current holding of 4.70% [2] - Kinsin Reproductive (01951) decreased by 1.81%, now at 47.25% [2] - Shandong Molong (00568) saw a reduction of 1.25%, with a holding of 54.75% [2] - Other significant decreases include Dongyang Sunshine Pharmaceutical (06887) at -0.84% (45.31%) and Oriental Electric (01072) at -0.87% (37.70%) [2] Group 3: Five-Day Holding Changes - Over the last five trading days, Hang Seng China Enterprises (02828) had the highest increase at +8.52%, with a holding of 10.79% [3] - Yimai Sunshine (02522) increased by 4.91%, maintaining a holding of 39.10% [3] - Southern Hang Seng Technology (03033) rose by 4.08%, now at 62.57% [3] Group 4: Twenty-Day Holding Changes - In the last twenty days, Changfei Optical Fiber (06869) saw a significant increase of 23.37%, with a holding of 55.53% [4] - Yimai Sunshine (02522) also increased by 10.46%, maintaining a holding of 39.10% [4] - Other notable increases include Meizhong Jiahe (02453) at +11.06% (37.00%) [4]

Group 1 - The core point of the article highlights that Jinxin Reproductive Medicine (01951) experienced a 5.03% decline in stock price, trading at 3.21 HKD per share with a transaction volume of 216 million HKD as of 14:40 on August 20 [1] - Jinxin Reproductive Medicine is a leading assisted reproductive service provider in China and the US, operating multiple hospitals and medical centers, primarily offering assisted reproductive services and related treatments [1] - According to a Frost & Sullivan report, in 2018, the company ranked third in China's assisted reproductive services market, conducting 20,958 in vitro fertilization cycles, with a market share of approximately 3.1%, and ranked first among non-state-owned assisted reproductive service providers [1] Group 2 - As of the 2024 annual report, Jinxin Reproductive Medicine reported total revenue of 2.812 billion HKD and a net profit of 283 million HKD [2] - The company is set to disclose its interim report for the fiscal year 2025 on August 25 [3]

Core Viewpoint - Jinxin Reproductive Medicine (01951) is experiencing a decline in stock price, currently down over 4%, with a trading price of HKD 3.25 and a transaction volume of HKD 118 million. The company has issued a profit warning, expecting a loss of no more than RMB 1.09 billion for the first half of the year, compared to a profit of RMB 190 million in the same period last year. The anticipated loss is primarily due to impairment and provisions related to goodwill, intangible assets, and other financial assets in its operations in the United States and Laos [1][1][1]. Company Summary - Jinxin Reproductive Medicine's stock price has dropped by 3.85% as of the latest report [1]. - The company plans to review its mid-year results for 2025 on August 25 [1]. - The expected loss of up to RMB 1.09 billion marks a significant decline from the previous year's profit of RMB 190 million [1]. - The primary reasons for the anticipated loss include impairments and provisions related to goodwill and intangible assets in its U.S. and Laos operations [1].

消息面上，锦欣生殖拟于8月25日(下周一)审议2025年中期业绩。公司此前发布盈警称，按国际财务报 告准则，预计上半年亏损不超过10.9亿人民币，相较去年同期纯利1.9亿人民币。预期亏损主要源于集团 在美国及老挝业务的若干商誉、无形资产及其他金融资产确认减值及拨备。 智通财经APP获悉，锦欣生殖(01951)现跌超4%，截至发稿，跌3.85%，报3.25港元，成交额1.18亿港 元。 ...

Core Viewpoint - Jinxin Reproductive Medicine (01951) experienced a significant stock price increase of 10.48% on August 18, reaching HKD 3.48 per share with a trading volume of HKD 296 million [1] Company Overview - Jinxin Reproductive Medicine Group Limited is a leading assisted reproductive service provider in China and the United States, operating multiple hospitals and medical centers that primarily offer assisted reproductive services and related treatments [1] - According to a Frost & Sullivan report, in 2018, the company ranked third in China's assisted reproductive services market, conducting 20,958 in vitro fertilization (IVF) egg retrieval cycles, with a market share of approximately 3.1%, and ranked first among non-state-owned assisted reproductive service providers [1] Financial Performance - As of the 2024 annual report, Jinxin Reproductive Medicine reported total revenue of HKD 2.812 billion and a net profit of HKD 283 million [2] Upcoming Events - Jinxin Reproductive Medicine is scheduled to disclose its interim report for the fiscal year 2025 on August 25 [3]

Key Points - The top three companies with net inflows from southbound funds are Xinda Biopharmaceutical (01801) with 835 million, China Life (02628) with 403 million, and AIA Insurance (01299) with 373 million [1][2] - The top three companies with net outflows are the Tracker Fund of Hong Kong (02800) with -6.679 billion, Hang Seng China Enterprises (02828) with -2.584 billion, and Anta Sports (02020) with -782 million [1][2] - In terms of net inflow ratio, Canggang Railway (02169) leads with 66.05%, followed by Bosideng (03998) with 49.50%, and Zhengzhou Bank (06196) with 48.61% [1][2] - The companies with the highest net outflow ratios include Skyworth Group (00751) at -52.19%, Anta Sports (02020) at -50.20%, and Ruipu Lanjun (00666) at -44.79% [1][2] Net Inflow Rankings - The top ten companies by net inflow include: - Xinda Biopharmaceutical (01801) with 835 million and a closing price of 95.000 (+8.82%) [2] - China Life (02628) with 403 million and a closing price of 22.800 (+0.71%) [2] - AIA Insurance (01299) with 373 million and a closing price of 76.400 (+3.03%) [2] - Other notable companies include Ideal Automotive (02015) with 365 million and a closing price of 97.150 (+3.30%) [2] Net Outflow Rankings - The top ten companies by net outflow include: - Tracker Fund of Hong Kong (02800) with -6.679 billion and a closing price of 26.080 (+2.35%) [2] - Hang Seng China Enterprises (02828) with -2.584 billion and a closing price of 93.760 (+2.76%) [2] - Anta Sports (02020) with -782 million and a closing price of 90.000 (+0.22%) [2] - Other significant outflows include Alibaba (09988) with -267 million and a closing price of 123.700 (+6.09%) [2] Net Inflow Ratio Rankings - The top companies by net inflow ratio include: - Canggang Railway (02169) with 66.05% and a closing price of 1.310 (-0.76%) [3] - Bosideng (03998) with 49.50% and a closing price of 4.600 (+0.66%) [3] - Zhengzhou Bank (06196) with 48.61% and a closing price of 1.410 (-2.08%) [3] Net Outflow Ratio Rankings - The top companies by net outflow ratio include: - Skyworth Group (00751) with -52.19% and a closing price of 3.260 (+1.24%) [3] - Anta Sports (02020) with -50.20% and a closing price of 90.000 (+0.22%) [3] - Ruipu Lanjun (00666) with -44.79% and a closing price of 12.160 (+5.28%) [3]

Investment Rating - The report maintains a "Buy" rating for Galaxy Entertainment, highlighting the resilience of the gaming industry and the long-term growth potential of the company [6]. Core Insights - Galaxy Entertainment achieved a net revenue of HKD 12 billion in Q2 2025, representing an 8% quarter-on-quarter increase and a 10% year-on-year increase. The adjusted EBITDA was HKD 3.2 billion, with a 7% quarter-on-quarter increase but a 1% year-on-year decline. Key revenue metrics have recovered to 82%, 130%, 138%, and 31% of 2019 levels for total gross revenue, mass market revenue, slot machine revenue, and VIP turnover, respectively [6][8]. - The company has a net cash position of HKD 30.3 billion as of June 30, 2025, and announced an interim dividend of HKD 0.70 per share, with a payout ratio of 58%, up from 50% in 2024 [6][8]. Summary by Sections 1. Overseas Social Services - Galaxy Entertainment's Q2 2025 performance shows a recovery in various revenue streams, with EBITDA returning to 79% of 2019 levels. The Capella Hotel is in trial operation, with full opening expected soon. The Macau Galaxy Phase IV project is progressing, with completion expected in 2027 [6][8]. 2. Overseas Pharmaceuticals - The 2025 medical insurance directory and commercial insurance innovative drug directory preliminary review has been published, with 534 out of 718 submissions passing the initial review. The new directory includes several CAR-T products and other innovative drugs [10][12]. 3. Domestic Pharmaceutical Companies - Crystal Holdings expects a revenue of at least HKD 500 million in H1 2025, a year-on-year increase of approximately 387%. In contrast, Jinxin Reproductive expects a net loss of no more than HKD 1.09 billion due to asset impairments [11][12]. 4. Overseas Pharmaceutical Company Updates - Insmed's DPP-1 inhibitor, BRINSUPRI, has received FDA approval for treating non-cystic fibrosis bronchiectasis. Novartis's BAFF-R monoclonal antibody has met primary endpoints in two Phase III studies for treating active Sjögren's syndrome [13][14]. 5. Investment Recommendations - The report suggests focusing on innovative drugs and pharmaceutical companies with strong clinical pipelines, including companies like BeiGene, Innovent Biologics, and others [15]. 6. Market Performance - The Hang Seng Healthcare Index rose by 3.50%, outperforming the Hang Seng Index by 1.75 percentage points, indicating a positive market sentiment towards healthcare stocks [8].